64 results match your criteria: "British Columbia Cancer Agency and The University of British Columbia[Affiliation]"
Recent Results Cancer Res
December 2003
Lung Tumour Group, The British Columbia Cancer Agency and The University of British Columbia, West 10 Avenue, Vancouver, BC V5Z 4E6, Canada.
Lung cancer is a major health problem world-wide. Former heavy smokers retain a significant risk for lung cancer after smoking cessation. With a large population of current and former smokers at risk, an alternative cancer control strategy such as chemoprevention needs to be developed to reduce lung cancer mortality especially for smokers who have followed medical advice to give up smoking.
View Article and Find Full Text PDFLeuk Lymphoma
April 2003
The Leukemtia/Bone Marrow Transplantation Program of British Columbia: Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induction chemotherapy for acute myelogenous leukemia.
View Article and Find Full Text PDFLeuk Lymphoma
July 2002
Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver Island Centre, Victoria, Canada.
Elderly patients with Hodgkin's lymphoma (HL) have a worse outcome than young patients. In an effort to improve the outcome in elderly HL patients, we used a 5-drug chemotherapy regimen called ODBEP (vincristine, doxorubicin, bleomycin, etoposide, prednisone) from 1986-1995. We hoped that by increasing dose intensity through delivery of treatment without delays, and increasing the number of non-cross-resistant chemotherapeutic drugs that were selected for minimal cumulative myelotoxicity, we might improve the cure rate in elderly patients with Hodgkin's lymphoma.
View Article and Find Full Text PDFJ Natl Cancer Inst
July 2002
Department of Respiratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Background: Results from preclinical studies have suggested that the organosulfur compound anethole dithiolethione (ADT) may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia.
Methods: One hundred twelve current and former smokers with a smoking history of at least 30 pack-years and at least one site of bronchial dysplasia identified by an autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive placebo or ADT at 25 mg orally thrice daily for 6 months.
Ann Oncol
December 2002
Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Genes Chromosomes Cancer
April 2001
Division of Pathology and Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada.
Follicular lymphoma is characterized by the t(14;18) in up to 85% of cases. Almost all cases display evidence of secondary chromosomal alterations at initial diagnosis. The influence of recurrent secondary changes on disease progression has not been fully determined.
View Article and Find Full Text PDFBone Marrow Transplant
June 1999
Leukemia/Bone Marrow Transplantation Program of British Columbia: Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency and the University of British Columbia, Canada.
This analysis compares the regimen-related toxicity (RRT) and overall non-relapse mortality (NRM) in Hodgkin's disease patients conditioned with either CBV (cyclophosphamide, BCNU (carmustine), and VP16-213 (etoposide)) (26 patients) or CBVP (CBV + cisplatin) (68 patients) followed by autologous stem cell transplantation (ASCT). CBVP included a continuous infusion rather than intermittent doses of etoposide, a lower BCNU dose and the addition of cisplatin. RRT and NRM were determined for each regimen and compared; risk factors for each were examined by multivariate analysis.
View Article and Find Full Text PDFExp Hematol
June 1999
Terry Fox Laboratory, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Ann Oncol
March 1999
Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Background: Lymphomas of mucosa associated lymphoid tissue (MALT) are a special type of extranodal lymphoma, possibly related to chronic antigenic stimulation. Increased cancer susceptibility may also contribute to the development of MALT lymphoma (MALToma). It has been suggested that patients with MALToma have an increased incidence of other malignancies.
View Article and Find Full Text PDFJ Natl Cancer Inst
April 1999
Department of Respiratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Background: Lung cancer is the most common cause of cancer death in North American women. Because smoking-related changes in the bronchial epithelium and in lung function have not been studied in detail in women, we used fluorescence bronchoscopy-directed biopsy to determine the prevalence of high-grade preinvasive lesions in former and current smokers of both sexes.
Methods: Spirometry, white-light bronchoscopy, and fluorescence bronchoscopy were performed in 189 women and 212 men older than 40 years of age who had smoked 20 pack-years or more (pack-years = number of packs of cigarettes smoked per day x number of years of smoking).
Blood
August 1998
Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
The purpose of this study was to compare the relative risk of second malignancies in a cohort of patients with hairy cell leukemia (HCL) against the normal population. Potential effects of type of treatment and duration of follow-up and the site distribution of cancer were also examined. Between 1976 and 1996, 117 patients were diagnosed with HCL in British Columbia who were referred to the British Columbia Cancer Agency (BCCA) for treatment.
View Article and Find Full Text PDFAnn Oncol
October 1997
Division of Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
Background: Low grade malignant lymphomas arising from mucosa associated lymphoid tissue (MALT) represent a distinct clinicopathological entity. The cytogenetic findings and molecular genetics of MALT lymphomas remain minimally defined. Cytogenetic studies infrequently constitute part of the diagnostic work-up of MALT lymphomas, most commonly due to small biopsy size and their extranodal localization.
View Article and Find Full Text PDFAm J Clin Pathol
November 1997
Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
We describe the histologic and immunohistochemical findings in specimens from bone marrow (BM) biopsies performed for staging purposes in 13 patients with a previous tissue-based diagnosis of T-cell-rich B-cell lymphoma (TCRBCL). Bone marrow involvement was found in 8 (62%) of 13 cases and was often paratrabecular. The histologic appearance was not pathognomonic of TCRBCL, with the differential diagnosis including Hodgkin's disease and peripheral T-cell lymphoma.
View Article and Find Full Text PDFAm J Clin Pathol
September 1997
Division of Laboratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
We conducted this study to assess the clinical utility of heteroduplex analysis of polymerase chain reaction (PCR) products for Tgamma gene rearrangements in the diagnosis of T-cell lymphoproliferative disorders (LPDs) using a single set of consensus primers. This method was used to study 103 cases using fresh or frozen tissue. These included 62 cases of T-cell LPDs, 25 cases of B-cell LPDs, 3 cases of anaplastic large cell lymphomas of undefined lineage, and 13 cases of reactive disorders.
View Article and Find Full Text PDF